MedTrace Logo

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

NCT04762875 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2024-11-06

Study results available
· View outcomes & findings →

Summary

This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies. MGTA-145, the new medicine, will be given with plerixafor.

Conditions

Interventions

BIOLOGICAL

MGTA-145

MGTA-145 will be be administered as an IV infusion

BIOLOGICAL

Plerixafor

240 µg/kg subcutaneously

Sponsors & Collaborators

  • National Marrow Donor Program

    collaborator OTHER

  • Ensoma

    lead INDUSTRY

Principal Investigators

  • Steven Devine, MD · National Marrow Donor Program

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-16
Primary Completion
2021-09-14
Completion
2022-03-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04762875 on ClinicalTrials.gov